|
|
| (59 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | {{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32293910|t=2020. The Science Underlying COVID-19: Implications for the Cardiovascular System |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32378801|t=2020. Comprehensive overview of COVID-19 based on current evidence |pdf=|usr=}}
| + | |
| − | {{tp|p=32374001|t=2020. Clinical display, diagnostics and genetic implication of novel Coronavirus (COVID-19) epidemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32374000|t=2020. An update on the status of COVID-19: a comprehensive review |pdf=|usr=}}
| + | |
| − | {{tp|p=32373999|t=2020. Coronavirus disease 2019: a clinical review |pdf=|usr=}}
| + | |
| − | {{tp|p=32373998|t=2020. The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review |pdf=|usr=}}
| + | |
| − | {{tp|p=32105049|t=2020. Novel coronavirus COVID-19: an overview for emergency clinicians|pdf=|usr=}}
| + | |
| − | {{tp|p=32207910|t=2020. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians|pdf=|usr=}}
| + | |
| − | {{tp|p=32273490|t=2020. Coronavirus Disease 2019 (COVID-19) in Children - What We Know So Far and What We Do Not |pdf=|usr=}}
| + | |
| − | {{tp|p=32378132|t=ä. COVID-19 (SARS-CoV-2 Infection) and Children: Pediatric Neurologist?s Perspective |pdf=|usr=}}
| + | |
| | | | |
| − |
| |
| − |
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32270695|t=2020. Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19: ... |pdf=|usr=}}
| |
| − | {{tp|p=32357975|t=2020. Early intervention likely improves mortality in COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32360710|t=2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes |pdf=|usr=}}
| |
| − | {{ttp|p=32374007|t=2020. Current practice and potential strategy in diagnosing COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372742|t=ä. Asymptomatic SARS-CoV-2 infections: What do we need to know?|pdf=|usr=}}
| |
| − | {{tp|p=32378044|t=ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32364404|t=2020. Establishment and Management of Mechanical Circulatory Support During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{ttp|p=32366580|t=2020. Respiratory advice for the non-respiratory physician in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32353223|t=2020. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32353224|t=2020. Home ventilators for invasive ventilation of patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32351196|t=2020. Initial experiences from patients with COVID-19 on ventilatory support in Denmark |pdf=|usr=}}
| |
| − | {{ttp|p=32375488|t=ä. Respiratory management in severe acute respiratory syndrome coronavirus 2 infection |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32191623|t=2020. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32172228|t=2020. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32242831|t=2020. Clinical laboratory and SARS-CoV-2 infection: where do we stand?|pdf=|usr=}}
| |
| − | {{tp|p=32242829|t=2020. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients |pdf=|usr=}}
| |
| − | {{tp|p=32301750|t=2020. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays |pdf=|usr=}}
| |
| − | {{tp|p=32301749|t=2020. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics |pdf=|usr=}}
| |
| − | {{tp|p=32301748|t=2020. Clinical chemistry tests for patients with COVID-19 - important caveats for interpretation |pdf=|usr=}}
| |
| − | {{tp|p=32301745|t=2020. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32286242|t=2020. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{ttp|p=32378969|t=2020. Spectroscopy as a tool for detection and monitoring of Coronavirus (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32332319|t=2020. 18F-FDG PET/CT and Serial Chest CT Findings in a COVID-19 Patient With Dynamic Clinical Characteristics in Different Period |pdf=|usr=}}
| |
| − | {{tp|p=32196453|t=2020. Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32239532|t=ä. Our Italian experience using lung ultrasound for identification, grading and serial follow?up of severity of lung involvement for management of patients with COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32239525|t=ä. Radiologic chest CT findings from COVID?19 in Orleans Parish, Louisiana |pdf=|usr=}}
| |
| − | {{tp|p=32373990|t=2020. Radiological role in the detection, diagnosis and monitoring for the coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32273489|t=2020. Serial Computed Tomography Findings in a Child with Coronavirus Disease (COVID-19) Pneumonia |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| − | {{tp|p=32333581|t=2020. Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience |pdf=|usr=}}
| |
| − | {{tp|p=32378021|t=ä. Tracheobronchitis signs observed on ventilation lung scintigraphy during the course of COVID-19 infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32367648|t=2020. SARS-CoV-2 variants: Relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment?|pdf=|usr=}}
| |
| − | {{tp|p=32342578|t=2020. The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291894|t=2020. Cytosine drives evolution of SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32338224|t=2020. Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32306452|t=2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?|pdf=|usr=}}
| |
| − | {{tp|p=32363391|t=ä. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | | | |
| Zeile 91: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32119647|t=2020. Laboratory abnormalities in patients with COVID-2019 infection |pdf=|usr=}}
| |
| − | {{tp|p=32172227|t=2020. Laboratory abnormalities in children with novel coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32352397|t=2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study |pdf=|usr=}}
| |
| − | {{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32301746|t=2020. Routine blood tests as a potential diagnostic tool for COVID-19 |pdf=|usr=}}
| |
| − | {{ttp|p=32286245|t=2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32365221|t=2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32315487|t=2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}}
| |
| − | {{tp|p=32376308|t=ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 107: |
Zeile 39: |
| | | | |
| | | | |
| − | ----
| |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32294809|t=2020. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis |pdf=|usr=}}
| |
| − | {{tp|p=32246845|t=2020. SARS?CoV?2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells |pdf=|usr=}}
| |
| − | {{tp|p=32353898|t=2020. Histopathology and genetic susceptibility in COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32367579|t=2020. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| | + | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32277530|t=ä. COVID?19 and SARS: Differences and similarities |pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| Zeile 127: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32301747|t=2020. Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children |pdf=|usr=}}
| |
| − | {{tp|p=32292053|t=2020. Severe Pneumonia Due to SARS-CoV-2 and Respiratory Syncytial Virus Infection: A Case Report |pdf=|usr=}}
| |
| − | {{tp|p=32362302|t=ä. To alert coinfection of COVID-19 and dengue virus in developing countries in the dengue-endemic area |pdf=|usr=}}
| |
| − | {{tp|p=32378044|t=ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32330083|t=2020. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence |pdf=|usr=}}
| + | |
| − | {{tp|p=32172226|t=2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32333581|t=2020. Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32333579|t=2020. (clin-hemorheol-microcirc) COVID-19 |pdf=|usr=}}
| + | |
| − | {{ttp|p=32294809|t=2020. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis |pdf=|usr=}}
| + | |
| − | {{tp|p=32374381|t=ä. Large saddle pulmonary embolism in a woman infected by COVID-19 pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 149: |
Zeile 65: |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Heart]]'''
| |
| − | {{tp|p=32352306|t=2020. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32251612|t=2020. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32243205|t=2020. The Variety of Cardiovascular Presentations of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32298134|t=2020. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings |pdf=|usr=}}
| |
| − | {{ttp|p=32297796|t=2020. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32286863|t=2020. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap!|pdf=|usr=}}
| |
| − | {{ttp|p=32354733|t=2020. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know |pdf=|usr=}}
| |
| − | {{tp|p=32379308|t=ä. Multivessel spontaneous coronary artery dissection presenting in a patient with severe acute SARS-CoV-2 respiratory infection |pdf=|usr=}}
| |
| − | {{tp|p=32374405|t=ä. ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19 acute respiratory distress syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32374373|t=ä. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32275347|t=2020. Myocardial localization of coronavirus in COVID-19 cardiogenic shock |pdf=|usr=}}
| |
| − | {{tp|p=32354799|t=2020. COVID-19 and acute myocardial injury: the heart of the matter or an innocent bystander?|pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Heart]]''' |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32371417|t=2020. Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32379592|t=2020. Emerging evidence for neuropsycho-consequences of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333819|t=2020. COVID-19: what if the brain had a role in causing the deaths?|pdf=|usr=}}
| + | |
| − | {{ttp|p=32333487|t=2020. Does SARS-Cov-2 invade the brain? Translational lessons from animal models |pdf=|usr=}}
| + | |
| − | {{tp|p=32320508|t=2020. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study |pdf=|usr=}}
| + | |
| − | {{tp|p=32301553|t=2020. Lack of dyspnea in patients with Covid-19: another neurological conundrum?|pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32282312|t=2020. A Case of COVID-19 Pneumonia in a Young Male with Full Body Rash as a Presenting Symptom |pdf=|usr=}}
| |
| − | {{tp|p=32369632|t=2020. Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32358996|t=2020. Skin signs resembling vascular acrosyndromes during the COVID-19 outbreak in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32302422|t=2020. Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East |pdf=|usr=}}
| |
| − | {{tp|p=32378284|t=2020. Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32341078|t=2020. COVID-19 patients presenting with afebrile acute abdominal pain |pdf=|usr=}}
| |
| − | {{tp|p=32253163|t=2020. The occurrence of diarrhea in COVID-19 patients |pdf=|usr=}}
| |
| − | {{ttp|p=32314455|t=2020. COVID-19 infection may cause ketosis and ketoacidosis |pdf=|usr=}}
| |
| − | {{tp|p=32349002|t=2020. COVID-19: Don`t neglect the Gastrointestinal Tract!|pdf=|usr=}}
| |
| − | {{tp|p=32335962|t=2020. COVID-19 and gastrointestinal endoscopy: what should be taken into account?|pdf=|usr=}}
| |
| − | {{tp|p=32335946|t=2020. Gastrointestinal endoscopy in the era of the acute pandemic of coronavirus disease 2019: Recommendations by Japan Gastroenterological Endoscopy Society (Issued on April 9th, 2020) |pdf=|usr=}}
| |
| − | {{tp|p=32281689|t=2020. COVID-19 and gastrointestinal endoscopies: current insights and emergent strategies |pdf=|usr=}}
| |
| − | {{tp|p=32234303|t=2020. Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32327413|t=2020. Genetic Roadmap for Kidney Involvement of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32377468|t=ä. First Case of an Infant with COVID-19 in the Middle East |pdf=|usr=}}
| |
| − | {{tp|p=32320270|t=2020. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32282224|t=2020. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations |pdf=|usr=}}
| |
| − | {{tp|p=32345646|t=2020. BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte) |pdf=|usr=}}
| |
| − | {{tp|p=32286246|t=2020. COVID-19 infections are also affected by human ACE1 D/I polymorphism |pdf=|usr=}}
| |
| − | {{tp|p=32112082|t=2020. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load |pdf=|usr=}}
| |
| − | {{tp|p=32220930|t=2020. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32342637|t=2020. COVID-19 and obesity |pdf=|usr=}}
| |
| − | {{tp|p=32292054|t=2020. SARS-CoV-2 Infection in a 2-Week-Old Male With Neutropenia |pdf=|usr=}}
| |
| − | {{tp|p=32255491|t=2020. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32320478|t=2020. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence |pdf=|usr=}}
| |
| − | {{tp|p=32237261|t=ä. The COVID?19 outbreak and rheumatologic skin diseases |pdf=|usr=}}
| |
| − | {{tp|p=32259878|t=ä. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID?19: Will cases of psoriasis increase after COVID?19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32375909|t=ä. Impact of Fundamental Diseases on Patients With COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32129518|t=ä. Angiotensin receptor blockers as tentative SARS?CoV?2 therapeutics |pdf=|usr=}}
| |
| − | {{tp|p=32233013|t=ä. Diabetes is a risk factor for the progression and prognosis of COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32374012|t=2020. Mortality rate and gender differences in COVID-19 patients dying in Italy: A comparison with other countries |pdf=|usr=}}
| |
| − | {{tp|p=32189428|t=ä. Is nicotine exposure linked to cardiopulmonary vulnerability to COVID?19 in the general population?|pdf=|usr=}}
| |
| − | {{tp|p=32376408|t=ä. Clinical Characteristics and Outcomes of COVID-19 Among Patients with Pre-Existing Liver Disease in United States: A Multi-Center Research Network Study |pdf=|usr=}}
| |
| − | {{tp|p=32369240|t=2020. Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind |pdf=|usr=}}
| |
| − | {{tp|p=32367558|t=2020. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32356577|t=2020. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration |pdf=|usr=}}
| |
| − | {{tp|p=32359088|t=2020. RAAS blockers in hypertension posing a higher risk towards the COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32362061|t=2020. (pat.on)Dupilumab and COVID-19: What should we expect?|pdf=|usr=}}
| |
| − | {{tp|p=32259611|t=2020. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used) |pdf=|usr=}}
| |
| − | {{tp|p=32356926|t=2020. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32304146|t=2020. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections |pdf=|usr=}}
| |
| − | {{tp|p=32329083|t=2020. (ang.)COVID-19 transmission through host cell directed network of GPCR |pdf=|usr=}}
| |
| − | {{tp|p=32234728|t=2020. EMA advice on the use of NSAIDs for Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32295811|t=2020. EMA advice on renin-angiotensin system medicines during covid-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32357072|t=2020. CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA |pdf=|usr=}}
| |
| − | {{tp|p=32376075|t=2020. Oligohydramnion in COVID19 |pdf=|usr=}}
| |
| − | {{tp|p=32290680|t=2020. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers |pdf=|usr=}}
| |
| − | {{tp|p=32310915|t=2020. ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2 |pdf=|usr=}}
| |
| − | {{tp|p=32354990|t=2020. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study |pdf=|usr=}}
| |
| − | {{tp|p=32239590|t=ä. Clinical findings in a patient with haemophilia A affected by COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32362297|t=ä. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32234453|t=2020. Follow-up of asymptomatic patients with SARS-CoV-2 infection |pdf=|usr=}}
| |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| Zeile 246: |
Zeile 93: |
| | | | |
| | | | |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32248675|t=2020. Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study|pdf=|usr=}}
| |
| − | {{tp|p=32378503|t=ä. Lessons Learned From Cases of COVID-19 Infection in South Korea |pdf=|usr=}}
| |
| − | {{tp|p=32352401|t=2020. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States |pdf=|usr=}}
| |
| − | {{tp|p=32314503|t=2020. Obesity and SARS-CoV-2: a population to safeguard |pdf=|usr=}}
| |
| − | {{tp|p=32273181|t=2020. COVID-19 in a Kidney Transplant Patient |pdf=|usr=}}
| |
| − | {{tp|p=32249089|t=2020. Identification of Kidney Transplant Recipients with Coronavirus Disease 2019 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Registries]]''' | + | *'''[[Case series]]''' |
| | | | |
| | | | |
| − | ----
| + | *'''[[Registries]]''' |
| | | | |
| | | | |
| Zeile 266: |
Zeile 106: |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32379692|t=ä. Traditional Chinese Medicine treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32379639|t=2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines |pdf=|usr=}}
| |
| − | {{ttp|p=32271624|t=2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis?|pdf=|usr=}}
| |
| − | {{tp|p=32333649|t=2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene |pdf=|usr=}}
| |
| − | {{tp|p=32378737|t=2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32356569|t=2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology |pdf=|usr=}}
| |
| − | {{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}}
| |
| − | {{tp|p=32350860|t=2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32348551|t=2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data |pdf=|usr=}}
| |
| − | {{tp|p=32302411|t=2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}}
| |
| − | {{tp|p=32345063|t=2020. Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32315229|t=2020. COVID-19 and the CRISPR Community Response |pdf=|usr=}}
| |
| − | {{tp|p=32321407|t=2020. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study |pdf=|usr=}}
| |
| − | {{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}}
| |
| − | {{tp|p=32334502|t=2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment|pdf=|usr=}}
| |
| − | {{tp|p=32133962|t=2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China |pdf=|usr=}}
| |
| − | {{tp|p=32314492|t=ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32237190|t=ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy |pdf=|usr=}}
| |
| − | {{tp|p=32227357|t=ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight |pdf=|usr=}}
| |
| − | {{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32374010|t=2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32374009|t=2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32369103|t=ä. Sacubitril/valsartan in COVID-19 patients: the need for trials |pdf=|usr=}}
| |
| − | {{tp|p=32373994|t=2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope |pdf=|usr=}}
| |
| − | {{tp|p=32373992|t=2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment |pdf=|usr=}}
| |
| − | {{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}}
| |
| − | {{tp|p=32362193|t=2020. Quadruple therapy for asymptomatic COVID-19 infection patients |pdf=|usr=}}
| |
| − | {{tp|p=32366131|t=2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine |pdf=|usr=}}
| |
| − | {{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}}
| |
| − | {{tp|p=32278585|t=2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab |pdf=|usr=}}
| |
| − | {{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32352361|t=2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists |pdf=|usr=}}
| |
| − | {{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
| |
| − | {{tp|p=32281695|t=2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases |pdf=|usr=}}
| |
| − | {{tp|p=32379896|t=2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs |pdf=|usr=}}
| |
| − | {{tp|p=31690127|t=2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach |pdf=|usr=}}
| |
| − | {{tp|p=32157732|t=ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| | + | *'''[[Biophysics of aerosols]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32369619|t=2020. Observations about sexual and other routes of SARS-CoV-2 (COVID-19) transmission and its prevention |pdf=|usr=}}
| |
| − | {{tp|p=32277746|t=2020. Fecal Shedding of SARS CoV-2: Implications for Disease Spread and Quarantine |pdf=|usr=}}
| |
| − |
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32170800|t=ä. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health?care workers fighting against coronavirus disease 2019 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32216640|t=2020. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32200663|t=2020. COVID-19 and Cardiovascular Disease |pdf=|usr=}}
| |
| − | {{tp|p=32312892|t=2020. Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32245780|t=2020. COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis |pdf=|usr=}}
| |
| − | {{tp|p=32241778|t=2020. Lessons from the Experience in Wuhan to Reduce Risk of COVID-19 Infection in Patients Undergoing Long-Term Hemodialysis |pdf=|usr=}}
| |
| − | {{tp|p=32222700|t=2020. On the Frontline of the COVID-19 Outbreak: Keeping Patients on Long-Term Dialysis Safe |pdf=|usr=}}
| |
| − | {{tp|p=32198130|t=2020. Mitigating Risk of COVID-19 in Dialysis Facilities |pdf=|usr=}}
| |
| − | {{tp|p=32345750|t=2020. Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32345749|t=2020. Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32332048|t=2020. How COVID-19 Has Changed the Management of Glomerular Diseases |pdf=|usr=}}
| |
| − | {{tp|p=32358234|t=2020. The American College of Nuclear Medicine Guidance on Operating Procedures for a Nuclear Medicine Facility During COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32324943|t=2020. How to manage smoke evacuation and filter pneumoperitoneum during laparoscopy to minimize potential viral spread: different methods from SoMe - a video vignette |pdf=|usr=}}
| |
| − | {{tp|p=32356955|t=2020. Clinical Pathway for Management of Suspected or Positive Novel Coronavirus-19 Patients With ST-Segment Elevation Myocardial Infarction |pdf=|usr=}}
| |
| − | {{tp|p=32275124|t=2020. Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm |pdf=|usr=}}
| |
| − | {{tp|p=32358977|t=2020. New clinical needs and strategies for care in children with neurodisability during COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32319209|t=2020. Challenge of managing patients with COVID-19 and acute behavioural disturbances |pdf=|usr=}}
| |
| − | {{tp|p=32295770|t=2020. Swivel-HEPA-ETT (SHE) bougie and HEPA-ETT (HE) methods for safe intubation while managing patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32259419|t=2020. Calculated decisions: COVID-19 calculators during extreme resource-limited situations |pdf=|usr=}}
| |
| − | {{tp|p=32375190|t=2020. Endoscopic ultrasound-guided gallbladder drainage as a strategy to overcome shortage of operating rooms and intensive care unit beds during Covid-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32380475|t=2020. Endocrinology in the time of COVID-19: Management of Cushing s syndrome |pdf=|usr=}}
| |
| − | {{tp|p=32369770|t=2020. Endocrinology in the time of COVID-19: Management of pituitary tumours |pdf=|usr=}}
| |
| − | {{tp|p=32380474|t=2020. Endocrinology in the time of COVID-19: Management of Hyponatraemia and Diabetes Insipidus |pdf=|usr=}}
| |
| − | {{tp|p=32379699|t=2020. Endocrinology in the time of COVID-19: Management of adrenal insufficiency |pdf=|usr=}}
| |
| − | {{tp|p=32352362|t=2020. Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China |pdf=|usr=}}
| |
| − | {{tp|p=32281754|t=2020. Managing patients in dialysis and with kidney transplant infected with Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32281757|t=2020. Covid-19 in patients on dialysis: infection prevention and control strategies |pdf=|usr=}}
| |
| − | {{tp|p=32372736|t=ä. Wearing face masks regardless of symptoms is crucial for preventing the spread of COVID-19 in hospitals |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32377486|t=ä. How Essential Is to Focus on Physician s Health and Burnout in Coronavirus (COVID-19) Pandemic?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32267243|t=2020. Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32349837|t=ä. COVID-19: the implications for suicide in older adults |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32376695|t=2020. Where have all the children gone? Decreases in paediatric emergency department attendances at the start of the COVID-19 pandemic of 2020 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − | {{tp|p=32366503|t=2020. Covid-19: NHS bosses told to assess risk to ethnic minority staff who may be at greater risk |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Economic aspects of the status hygienicus]]'''
| |
| − | *[https://www.weforum.org/agenda/2020/05/global-food-chains-disruption-covid19 global famine]
| |
| − | {{tp|p=32366510|t=2020. Covid-19: collateral damage of lockdown in India |pdf=|usr=}}
| |
| − | {{tp|p=32253178|t=2020. Covid-19 and the rise of racism |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Economic aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| Zeile 384: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32196426|t=2020. Seasonality of Respiratory Viral Infections |pdf=|usr=}}
| |
| − | {{tp|p=32351197|t=2020. COVID-19 is possibly a consequence of the anthropogenic biodiversity crisis and climate changes |pdf=|usr=}}
| |
| − | {{tp|p=32276290|t=ä. COVID?19: A relationship to climate and environmental conditions?|pdf=|usr=}}
| |
| − | {{tp|p=32373996|t=2020. The correlation between the spread of COVID-19 infections and weather variables in 30 Chinese provinces and the impact of Chinese government mitigation plans |pdf=|usr=}}
| |
| − | {{tp|p=32186951|t=2020. One Health approach and Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32373995|t=2020. Bioinformatic analysis indicates that SARS-CoV-2 is unrelated to known artificial coronaviruses |pdf=|usr=}}
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32364762|t=2020. At the Heart of the Matter: Unmasking and Addressing COVID-19 s Toll on Diverse Populations |pdf=|usr=}}
| + | |
| − | {{tp|p=32221515|t=2020. Spotlight on Jails: COVID-19 Mitigation Policies Needed Now |pdf=|usr=}}
| + | |
| − | {{ttp|p=32267544|t=2020. Quarantine alone or in combination with other public health measures to control COVID?19: a rapid review |pdf=|usr=}}
| + | |
| − | {{tp|p=32367739|t=2020. Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions |pdf=|usr=}}
| + | |
| − | {{tp|p=32187421|t=ä. COVID?19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?|pdf=|usr=}}
| + | |
| − | {{tp|p=32170898|t=ä. COVID?19 and rationally layered social distancing |pdf=|usr=}}
| + | |
| − | {{tp|p=32377056|t=ä. Lockdown?the only solution to defeat COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 408: |
Zeile 155: |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| − | {{tp|p=32366742|t=ä. Prolonged Viral RNA Shedding Duration in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32342849|t=2020. Case Report: Viral Shedding for 60 Days in a Woman with Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32297851|t=ä. Positive RT-PCR tests among discharged COVID-19 patients in Shenzhen, China |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| − | {{tp|p=32324421|t=2020. Raids on Immigrant Communities During the Pandemic Threaten the Country s Public Health |pdf=|usr=}}
| |
| − | {{tp|p=32366370|t=2020. Covid-19: Coroners needn t investigate PPE policy failures in deaths of NHS staff, new guidance says |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − |
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32227594|t=ä. Social media for rapid knowledge dissemination: early experience from the COVID?19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32213480|t=2020. Covid-19: how to be careful with trust and expertise on social media |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 429: |
Zeile 170: |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32374013|t=2020. Faced with 2019-nCoV outbreak, we have learned our lessons from SARS of 2003 |pdf=|usr=}}
| |
| − | {{tp|p=32374011|t=2020. Herd immunity and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32202659|t=2020. Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures |pdf=|usr=}}
| |
| − | {{tp|p=32376793|t=2020. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32355114|t=2020. Improper use of germicidal range ultraviolet lamp for household disinfection leading to phototoxicity in COVID-19 suspects |pdf=|usr=}}
| |
| − | {{tp|p=32302975|t=2020. Androgen hazards with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32279694|t=ä. Covid-19 and the N95 respirator shortage: Closing the gap |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | | | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | | | |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
